The present study aimed to explore basal FGL1 expression in six HCC cell lines (Hep3B, Huh7, HepG2, SNU387, SNU449, and SNU475) and investigate its relationship with susceptibility to sorafenib treatment. Here, FGL1 is linked to hepatocellular carcinoma.